Review




Structured Review

Becton Dickinson cd45.2 monoclonal antibody (104), apc-cy7
Cd45.2 Monoclonal Antibody (104), Apc Cy7, supplied by Becton Dickinson, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/cd45.2 monoclonal antibody (104), apc-cy7/product/Becton Dickinson
Average 90 stars, based on 1 article reviews
cd45.2 monoclonal antibody (104), apc-cy7 - by Bioz Stars, 2026-04
90/100 stars

Images



Similar Products

97
Revvity cd45 2 apc cy7
Cd45 2 Apc Cy7, supplied by Revvity, used in various techniques. Bioz Stars score: 97/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/cd45 2 apc cy7/product/Revvity
Average 97 stars, based on 1 article reviews
cd45 2 apc cy7 - by Bioz Stars, 2026-04
97/100 stars
  Buy from Supplier

96
Miltenyi Biotec cd45 2 apc cy7
Cd45 2 Apc Cy7, supplied by Miltenyi Biotec, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/cd45 2 apc cy7/product/Miltenyi Biotec
Average 96 stars, based on 1 article reviews
cd45 2 apc cy7 - by Bioz Stars, 2026-04
96/100 stars
  Buy from Supplier

94
Cytek Biosciences panel innate immune cells fluorochrome bv421 fitc apc pe cy7 bv785 ghost dye red 710 antigen cd45 2 cd11b cd11c f4 80 cd206 live
Panel Innate Immune Cells Fluorochrome Bv421 Fitc Apc Pe Cy7 Bv785 Ghost Dye Red 710 Antigen Cd45 2 Cd11b Cd11c F4 80 Cd206 Live, supplied by Cytek Biosciences, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/panel innate immune cells fluorochrome bv421 fitc apc pe cy7 bv785 ghost dye red 710 antigen cd45 2 cd11b cd11c f4 80 cd206 live/product/Cytek Biosciences
Average 94 stars, based on 1 article reviews
panel innate immune cells fluorochrome bv421 fitc apc pe cy7 bv785 ghost dye red 710 antigen cd45 2 cd11b cd11c f4 80 cd206 live - by Bioz Stars, 2026-04
94/100 stars
  Buy from Supplier

90
Becton Dickinson cd45.2 monoclonal antibody (104), apc-cy7
Cd45.2 Monoclonal Antibody (104), Apc Cy7, supplied by Becton Dickinson, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/cd45.2 monoclonal antibody (104), apc-cy7/product/Becton Dickinson
Average 90 stars, based on 1 article reviews
cd45.2 monoclonal antibody (104), apc-cy7 - by Bioz Stars, 2026-04
90/100 stars
  Buy from Supplier

90
Becton Dickinson cd45.2-apc/cy7 (104; 1:100)
a Schematic illustration of transwell assays in which LN3 T-ALL cells are cultured in the presence or absence of enriched tumor-associated myeloid cells in the same or opposite chambers to determine whether T-ALL cells require close contact with myeloid cells to survive. b Quantification of viable T-ALL cells in the chamber indicated in red 6–7 days after co-culture initiation. Results were normalized to the viability of T-ALL cells making physical contact with tumor-associated myeloid cells in the bottom chamber within each experiment. Bars depict the mean + SEM of cumulative data from n = 7 experiments, each with a distinct color-coded primary T-ALL; symbols represent the mean of 2-3 replicate wells per experiment. c Representative flow cytometry plots and ( d ) quantification ofcell surface integrin expression levels of transplanted LN3 T-ALL cells (red; <t>CD45.2</t> + CD5 + ) and host T cells (blue; CD45.1 + CD5 + ) from the same leukemic spleens, quantified as median fluorescence intensity (MFI) values by flow cytometry. Isotype control stains are shaded in gray. d Results were normalized to T-cell levels within each experiment. Data are compiled from n = 6 (ITGα4, ITGβ2) or 7 (ITGα9, ITGβ1, ITGαL) independent experiments, each with a distinct color-coded primary T-ALL; symbols represent individual mice. e Quantification of ICAM-1 (left) and VCAM-1 (right) protein levels on the indicated myeloid subsets from the spleens of healthy (blue) or leukemic (red) mice. Results were normalized to healthy controls within each subset. Bars depict the mean + SEM of cumulative data from n = 3 experiments, each with a distinct color-coded primary T-ALL; symbols represent individual mice. Statistical significance was determined by ( b ) a two-sided repeated measures one-way ANOVA with the Holm-Sidak correction, ( d ) two-sided paired Student t -tests, and ( e ) two-sided unpaired Student t -tests; P -values: *<0.05, **<0.01, ***<0.001. ns, not significant. Source data are provided as a Source Data file.
Cd45.2 Apc/Cy7 (104; 1:100), supplied by Becton Dickinson, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/cd45.2-apc/cy7 (104; 1:100)/product/Becton Dickinson
Average 90 stars, based on 1 article reviews
cd45.2-apc/cy7 (104; 1:100) - by Bioz Stars, 2026-04
90/100 stars
  Buy from Supplier

90
Becton Dickinson mouse anti-mouse cd45.2-apc-cy7
(A and B) Female Balb/c mice were intraperitoneally injected with PBS, LH01 (5 mg/kg), or LH05 (10 mg/kg) every 3 days, with body weight changes (A) and survival (B) monitored (n = 8). (C) Spleens of mice were extracted and weighed after euthanasia on day 5 (n = 4). (D and E) The percentages of splenic CD8 + T cells and NK cells are shown for populations of CD3 + and <t>CD45</t> + lymphocytes, respectively. (F and G) The number of CD8 + T cells (F) and NK cells (G) in peripheral blood was counted. (H and I) Blood samples were collected after euthanasia on day 5, and plasma cytokine levels were measured using ELISA (H), ALT and AST plasma levels were also quantified (I). All graphs show the mean ±SEM. * p < 0.05; ** p < 0.01; *** p < 0.001; ns, not significant.
Mouse Anti Mouse Cd45.2 Apc Cy7, supplied by Becton Dickinson, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/mouse anti-mouse cd45.2-apc-cy7/product/Becton Dickinson
Average 90 stars, based on 1 article reviews
mouse anti-mouse cd45.2-apc-cy7 - by Bioz Stars, 2026-04
90/100 stars
  Buy from Supplier

97
Revvity anti cd45 2 apc cy7
(A and B) Female Balb/c mice were intraperitoneally injected with PBS, LH01 (5 mg/kg), or LH05 (10 mg/kg) every 3 days, with body weight changes (A) and survival (B) monitored (n = 8). (C) Spleens of mice were extracted and weighed after euthanasia on day 5 (n = 4). (D and E) The percentages of splenic CD8 + T cells and NK cells are shown for populations of CD3 + and <t>CD45</t> + lymphocytes, respectively. (F and G) The number of CD8 + T cells (F) and NK cells (G) in peripheral blood was counted. (H and I) Blood samples were collected after euthanasia on day 5, and plasma cytokine levels were measured using ELISA (H), ALT and AST plasma levels were also quantified (I). All graphs show the mean ±SEM. * p < 0.05; ** p < 0.01; *** p < 0.001; ns, not significant.
Anti Cd45 2 Apc Cy7, supplied by Revvity, used in various techniques. Bioz Stars score: 97/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/anti cd45 2 apc cy7/product/Revvity
Average 97 stars, based on 1 article reviews
anti cd45 2 apc cy7 - by Bioz Stars, 2026-04
97/100 stars
  Buy from Supplier

Image Search Results


a Schematic illustration of transwell assays in which LN3 T-ALL cells are cultured in the presence or absence of enriched tumor-associated myeloid cells in the same or opposite chambers to determine whether T-ALL cells require close contact with myeloid cells to survive. b Quantification of viable T-ALL cells in the chamber indicated in red 6–7 days after co-culture initiation. Results were normalized to the viability of T-ALL cells making physical contact with tumor-associated myeloid cells in the bottom chamber within each experiment. Bars depict the mean + SEM of cumulative data from n = 7 experiments, each with a distinct color-coded primary T-ALL; symbols represent the mean of 2-3 replicate wells per experiment. c Representative flow cytometry plots and ( d ) quantification ofcell surface integrin expression levels of transplanted LN3 T-ALL cells (red; CD45.2 + CD5 + ) and host T cells (blue; CD45.1 + CD5 + ) from the same leukemic spleens, quantified as median fluorescence intensity (MFI) values by flow cytometry. Isotype control stains are shaded in gray. d Results were normalized to T-cell levels within each experiment. Data are compiled from n = 6 (ITGα4, ITGβ2) or 7 (ITGα9, ITGβ1, ITGαL) independent experiments, each with a distinct color-coded primary T-ALL; symbols represent individual mice. e Quantification of ICAM-1 (left) and VCAM-1 (right) protein levels on the indicated myeloid subsets from the spleens of healthy (blue) or leukemic (red) mice. Results were normalized to healthy controls within each subset. Bars depict the mean + SEM of cumulative data from n = 3 experiments, each with a distinct color-coded primary T-ALL; symbols represent individual mice. Statistical significance was determined by ( b ) a two-sided repeated measures one-way ANOVA with the Holm-Sidak correction, ( d ) two-sided paired Student t -tests, and ( e ) two-sided unpaired Student t -tests; P -values: *<0.05, **<0.01, ***<0.001. ns, not significant. Source data are provided as a Source Data file.

Journal: Nature Communications

Article Title: Integrin signaling is critical for myeloid-mediated support of T-cell acute lymphoblastic leukemia

doi: 10.1038/s41467-023-41925-z

Figure Lengend Snippet: a Schematic illustration of transwell assays in which LN3 T-ALL cells are cultured in the presence or absence of enriched tumor-associated myeloid cells in the same or opposite chambers to determine whether T-ALL cells require close contact with myeloid cells to survive. b Quantification of viable T-ALL cells in the chamber indicated in red 6–7 days after co-culture initiation. Results were normalized to the viability of T-ALL cells making physical contact with tumor-associated myeloid cells in the bottom chamber within each experiment. Bars depict the mean + SEM of cumulative data from n = 7 experiments, each with a distinct color-coded primary T-ALL; symbols represent the mean of 2-3 replicate wells per experiment. c Representative flow cytometry plots and ( d ) quantification ofcell surface integrin expression levels of transplanted LN3 T-ALL cells (red; CD45.2 + CD5 + ) and host T cells (blue; CD45.1 + CD5 + ) from the same leukemic spleens, quantified as median fluorescence intensity (MFI) values by flow cytometry. Isotype control stains are shaded in gray. d Results were normalized to T-cell levels within each experiment. Data are compiled from n = 6 (ITGα4, ITGβ2) or 7 (ITGα9, ITGβ1, ITGαL) independent experiments, each with a distinct color-coded primary T-ALL; symbols represent individual mice. e Quantification of ICAM-1 (left) and VCAM-1 (right) protein levels on the indicated myeloid subsets from the spleens of healthy (blue) or leukemic (red) mice. Results were normalized to healthy controls within each subset. Bars depict the mean + SEM of cumulative data from n = 3 experiments, each with a distinct color-coded primary T-ALL; symbols represent individual mice. Statistical significance was determined by ( b ) a two-sided repeated measures one-way ANOVA with the Holm-Sidak correction, ( d ) two-sided paired Student t -tests, and ( e ) two-sided unpaired Student t -tests; P -values: *<0.05, **<0.01, ***<0.001. ns, not significant. Source data are provided as a Source Data file.

Article Snippet: Cells were then stained with fluorescently labeled antibodies against anti-mouse CD45.1-PerCP/Cy5.5 (A20; 1:100), CD45.2-APC/Cy7 (104; 1:100), CD5-PE/Cy7 (53-7.3; 1:200), pIGF1R-Alexa Fluor 647 (K74-218; pY1131; BD Biosciences; 1:10), pAKT-PE or -Brilliant Violet 421 (J24-618; pS473; BD Biosciences; 1:10), pPYK2-PE (L68-1256.272; pY402; BD Biosciences; 1:10), pFAK (#3283; pY397; Cell Signaling Technology; 1:200), pFAK (#3284; pY925; Cell Signaling Technology; 1:50), pFAK (44–626 G; pY861; Invitrogen; 1:200), donkey anti-rabbit IgG-PE (Poly4064; 1:400), ILK (P83A9; 1:200), donkey anti-rabbit IgG-Alexa Fluor 488 (Jackson ImmunoResearch; 1:400) and goat anti-mouse IgG-Alexa Fluor 488 (Invitrogen; 1:400) antibodies.

Techniques: Cell Culture, Co-Culture Assay, Flow Cytometry, Expressing, Fluorescence

a The top 6 pathways upregulated in thymic T-ALL cells versus healthy thymocytes identified using Enrichr with WikiPathways 2019 Mouse gene sets. b , c ( b) Representative flow cytometry plots and ( c ) quantification of pFAK and pPYK2 levels in T-ALL (CD45.2 + CD5 + ) relative to host T cells (CD45.1 + CD5 + ) in the same leukemic spleens. Isotype control stain in gray. Results were normalized to mean MFIs of T cells and compiled from n = 6 independent experiments. d Quantification of pFAK and pPYK2 levels in splenic LN3 T-ALL from Icam1 +/- and Icam1 -/- hosts treated with an isotype control antibody from experiments in Supplementary Fig. . Results were normalized to the MFI of Icam1 +/- mice and compiled from n = 3 independent experiments; symbols represent individual mice. e Quantification of viable T-ALL cells in myeloid co-cultures treated 4 days after culture initiation with FAK/PYK2 dual inhibitors (PF-431396 or PF-562271) and quantified 2–3 days later. Results were normalized to DMSO treated control cultures and compiled from n = 3 independent experiments; symbols represent averages of 2–3 replicate wells. f , g ( f ) Representative flow cytometry plots and ( g ) quantification of pIGF1R levels in LN3 T-ALL cells co-cultured with myeloid cells and PF-562271 (0.1 μM) and/or IGF1 (100 ng/ml), or DMSO for 4–5 days. Results were normalized to DMSO-treated cultures and compiled from n = 3 independent experiments; symbols represent averages of 2-3 technical replicate wells. h Quantification of viable splenic T-ALL cells 4–5 days after co-culture with enriched myeloid cells +/- exogenous IGF1 (100 ng/ml) and/or PF-562271 (0.1 or 0.5 μM, as indicated). Results were normalized to T-ALL cells co-cultured with myeloid cells + DMSO alone and compiled from n = 3 independent experiments; symbols represent the average of 2-3 technical replicate wells per experiment. Bars represent means + SEM; red lines indicate normalized means of controls. Distinct primary T-ALLs are color-coded. Statistical significance was determined by ( a ) Fisher exact tests, ( c ) two-sided paired Student t -tests, ( d ) two-sided unpaired Student t -tests, and ( e , g , h ) a two-sided repeated measures one-way ANOVA with the Holm-Sidak correction: *<0.05, **<0.01, ***<0.001. ns, not significant. Source data are provided as a Source Data file.

Journal: Nature Communications

Article Title: Integrin signaling is critical for myeloid-mediated support of T-cell acute lymphoblastic leukemia

doi: 10.1038/s41467-023-41925-z

Figure Lengend Snippet: a The top 6 pathways upregulated in thymic T-ALL cells versus healthy thymocytes identified using Enrichr with WikiPathways 2019 Mouse gene sets. b , c ( b) Representative flow cytometry plots and ( c ) quantification of pFAK and pPYK2 levels in T-ALL (CD45.2 + CD5 + ) relative to host T cells (CD45.1 + CD5 + ) in the same leukemic spleens. Isotype control stain in gray. Results were normalized to mean MFIs of T cells and compiled from n = 6 independent experiments. d Quantification of pFAK and pPYK2 levels in splenic LN3 T-ALL from Icam1 +/- and Icam1 -/- hosts treated with an isotype control antibody from experiments in Supplementary Fig. . Results were normalized to the MFI of Icam1 +/- mice and compiled from n = 3 independent experiments; symbols represent individual mice. e Quantification of viable T-ALL cells in myeloid co-cultures treated 4 days after culture initiation with FAK/PYK2 dual inhibitors (PF-431396 or PF-562271) and quantified 2–3 days later. Results were normalized to DMSO treated control cultures and compiled from n = 3 independent experiments; symbols represent averages of 2–3 replicate wells. f , g ( f ) Representative flow cytometry plots and ( g ) quantification of pIGF1R levels in LN3 T-ALL cells co-cultured with myeloid cells and PF-562271 (0.1 μM) and/or IGF1 (100 ng/ml), or DMSO for 4–5 days. Results were normalized to DMSO-treated cultures and compiled from n = 3 independent experiments; symbols represent averages of 2-3 technical replicate wells. h Quantification of viable splenic T-ALL cells 4–5 days after co-culture with enriched myeloid cells +/- exogenous IGF1 (100 ng/ml) and/or PF-562271 (0.1 or 0.5 μM, as indicated). Results were normalized to T-ALL cells co-cultured with myeloid cells + DMSO alone and compiled from n = 3 independent experiments; symbols represent the average of 2-3 technical replicate wells per experiment. Bars represent means + SEM; red lines indicate normalized means of controls. Distinct primary T-ALLs are color-coded. Statistical significance was determined by ( a ) Fisher exact tests, ( c ) two-sided paired Student t -tests, ( d ) two-sided unpaired Student t -tests, and ( e , g , h ) a two-sided repeated measures one-way ANOVA with the Holm-Sidak correction: *<0.05, **<0.01, ***<0.001. ns, not significant. Source data are provided as a Source Data file.

Article Snippet: Cells were then stained with fluorescently labeled antibodies against anti-mouse CD45.1-PerCP/Cy5.5 (A20; 1:100), CD45.2-APC/Cy7 (104; 1:100), CD5-PE/Cy7 (53-7.3; 1:200), pIGF1R-Alexa Fluor 647 (K74-218; pY1131; BD Biosciences; 1:10), pAKT-PE or -Brilliant Violet 421 (J24-618; pS473; BD Biosciences; 1:10), pPYK2-PE (L68-1256.272; pY402; BD Biosciences; 1:10), pFAK (#3283; pY397; Cell Signaling Technology; 1:200), pFAK (#3284; pY925; Cell Signaling Technology; 1:50), pFAK (44–626 G; pY861; Invitrogen; 1:200), donkey anti-rabbit IgG-PE (Poly4064; 1:400), ILK (P83A9; 1:200), donkey anti-rabbit IgG-Alexa Fluor 488 (Jackson ImmunoResearch; 1:400) and goat anti-mouse IgG-Alexa Fluor 488 (Invitrogen; 1:400) antibodies.

Techniques: Flow Cytometry, Staining, Cell Culture, Co-Culture Assay

(A and B) Female Balb/c mice were intraperitoneally injected with PBS, LH01 (5 mg/kg), or LH05 (10 mg/kg) every 3 days, with body weight changes (A) and survival (B) monitored (n = 8). (C) Spleens of mice were extracted and weighed after euthanasia on day 5 (n = 4). (D and E) The percentages of splenic CD8 + T cells and NK cells are shown for populations of CD3 + and CD45 + lymphocytes, respectively. (F and G) The number of CD8 + T cells (F) and NK cells (G) in peripheral blood was counted. (H and I) Blood samples were collected after euthanasia on day 5, and plasma cytokine levels were measured using ELISA (H), ALT and AST plasma levels were also quantified (I). All graphs show the mean ±SEM. * p < 0.05; ** p < 0.01; *** p < 0.001; ns, not significant.

Journal: bioRxiv

Article Title: Next-generation anti-PD-L1/IL-15 immunocytokine elicits superior antitumor immunity in cold tumors with minimal toxicity

doi: 10.1101/2023.08.02.551593

Figure Lengend Snippet: (A and B) Female Balb/c mice were intraperitoneally injected with PBS, LH01 (5 mg/kg), or LH05 (10 mg/kg) every 3 days, with body weight changes (A) and survival (B) monitored (n = 8). (C) Spleens of mice were extracted and weighed after euthanasia on day 5 (n = 4). (D and E) The percentages of splenic CD8 + T cells and NK cells are shown for populations of CD3 + and CD45 + lymphocytes, respectively. (F and G) The number of CD8 + T cells (F) and NK cells (G) in peripheral blood was counted. (H and I) Blood samples were collected after euthanasia on day 5, and plasma cytokine levels were measured using ELISA (H), ALT and AST plasma levels were also quantified (I). All graphs show the mean ±SEM. * p < 0.05; ** p < 0.01; *** p < 0.001; ns, not significant.

Article Snippet: The following antibodies and reagents were used: mouse anti-mouse CD45.2-APC-Cy7 (BD Biosciences), hamster anti-mouse CD3e-FITC (BD Biosciences), rat anti-mouse CD4-PE (BD Biosciences), rat anti-mouse CD8a-BV510 (BD Biosciences), rat anti-mouse CD8a-APC (BD Biosciences), rat anti-mouse Nkp46-BV421 (BioLegend), rat anti-mouse Nkp46-Alexa Flour 647 (BD Biosciences), rat anti-mouse IFN-γ-BV786 (BD Biosciences), mouse anti-human/mouse Grazyme B-PE Cyanine 7 (BioLegend), rat anti-mouse CD8-FITC (BioLegend), rat anti-mouse CD44-PE (BioLegend), rat anti-mouse CD62L-APC (BD Biosciences).

Techniques: Injection, Enzyme-linked Immunosorbent Assay

Flow cytometry analysis of spleens and tumors of RM-1 tumor-bearing mice treated as described in . (A) The spleens of RM-1 tumor-bearing mice were extracted and weighed after euthanasia (n = 5). (B and C) The frequency of splenic CD4 + T cells (B) and CD8 + T cells (C) for CD3 + lymphocytes, respectively. (D) The ratio of CD4 + to CD8 + T cells was calculated. ( E ) The percentage of splenic NK cells for CD45 + lymphocytes was determined. (F) The expression of the memory cell markers CD62L and CD44 on splenic CD8 + T cells were assessed. (G-I) The percentage of intratumoral CD8 + T cells (G) within the population of CD3 + lymphocytes, and the frequency of IFNγ + (H) or perforin + (I) CD8 + T cells within the tumor were assessed. (J-L) The percentage of intratumoral NK cells (J) within the population of CD45 + lymphocytes, and the frequency of IFNγ + (K) or perforin + (L) NK cells within the tumor were determined. All graphs show the mean ±SEM. * p < 0.05; ** p < 0.01; *** p < 0.001; ns, not significant.

Journal: bioRxiv

Article Title: Next-generation anti-PD-L1/IL-15 immunocytokine elicits superior antitumor immunity in cold tumors with minimal toxicity

doi: 10.1101/2023.08.02.551593

Figure Lengend Snippet: Flow cytometry analysis of spleens and tumors of RM-1 tumor-bearing mice treated as described in . (A) The spleens of RM-1 tumor-bearing mice were extracted and weighed after euthanasia (n = 5). (B and C) The frequency of splenic CD4 + T cells (B) and CD8 + T cells (C) for CD3 + lymphocytes, respectively. (D) The ratio of CD4 + to CD8 + T cells was calculated. ( E ) The percentage of splenic NK cells for CD45 + lymphocytes was determined. (F) The expression of the memory cell markers CD62L and CD44 on splenic CD8 + T cells were assessed. (G-I) The percentage of intratumoral CD8 + T cells (G) within the population of CD3 + lymphocytes, and the frequency of IFNγ + (H) or perforin + (I) CD8 + T cells within the tumor were assessed. (J-L) The percentage of intratumoral NK cells (J) within the population of CD45 + lymphocytes, and the frequency of IFNγ + (K) or perforin + (L) NK cells within the tumor were determined. All graphs show the mean ±SEM. * p < 0.05; ** p < 0.01; *** p < 0.001; ns, not significant.

Article Snippet: The following antibodies and reagents were used: mouse anti-mouse CD45.2-APC-Cy7 (BD Biosciences), hamster anti-mouse CD3e-FITC (BD Biosciences), rat anti-mouse CD4-PE (BD Biosciences), rat anti-mouse CD8a-BV510 (BD Biosciences), rat anti-mouse CD8a-APC (BD Biosciences), rat anti-mouse Nkp46-BV421 (BioLegend), rat anti-mouse Nkp46-Alexa Flour 647 (BD Biosciences), rat anti-mouse IFN-γ-BV786 (BD Biosciences), mouse anti-human/mouse Grazyme B-PE Cyanine 7 (BioLegend), rat anti-mouse CD8-FITC (BioLegend), rat anti-mouse CD44-PE (BioLegend), rat anti-mouse CD62L-APC (BD Biosciences).

Techniques: Flow Cytometry, Expressing